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Chronic kidney disease (CKD) is common and an impor-tant independent risk factor for cardiovascular disease 
(CVD).1 This increased risk is partly explained by a high preva-
lence of traditional CVD risk factors, such as diabetes mellitus 
and hypertension.2 Dyslipidemia is also common in CKD and 
contributes to the development of accelerated atherosclerosis 
and CVD.3 HMG-CoA (hydroxymethylglutarate co-enzyme 
A) reductase inhibitors (statins) lower cholesterol, particu-
larly low-density lipoprotein–associated cholesterol (LDL-C) 
and have proven efficacy in the reduction of CVD risk in those 
with and without CKD.4,5 However, despite the use of statins, 
many patients with CKD continue to have elevated lipids.6 
Furthermore, the side effects associated with these drugs can 
limit their use.7 Thus, novel therapies that might lower cho-
lesterol both in patients established on-statin treatment and in 
those intolerant of statins would be of major clinical value.
PCSK9 (proprotein convertase subtilisin/kexin type 9) is a 
serine protease produced mainly in the liver and is an impor-
tant regulator of tissue LDL-R (LDL receptor) expression and 
cholesterol homeostasis.8 In the circulation, PCSK9 binds to 
cell surface LDL-R promoting their lysosomal degradation, 
leading to a rise in circulating LDL-C. Inhibition of circu-
lating PCSK9 using novel humanized monoclonal antibodies 
leads to important reductions in LDL-C in patients on and off 
statins.9,10 Recent preclinical studies have shown that PCSK9 
expression increases during systemic inflammation11 and with 
podocyte injury.12 Both are central features of CKD and con-
tributed to by ET-1 (endothelin-1).13
ET-1 is the most potent endogenous vasoconstrictor and 
plays an important role in the development and progression 
of CKD.13 The major pathological effects of ET-1 are medi-
ated via ETA (endothelin-A) receptors.13 Preclinical data using 
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ET receptor antagonists have suggested beneficial effects on 
circulating lipids and atherosclerosis,14 but subsequent clin-
ical studies have produced conflicting results, and none have 
explored potential mechanisms.15–19 Thus, we hypothesized 
that in a cohort of optimally-managed proteinuric patients 
with CKD, selective ETA receptor antagonism would lead to a 
reduction in circulating lipids and PCSK9.
Methods
Data relating to this study are available from the corresponding au-
thor on reasonable request. To test the paradigm that selective ETA 
antagonism can lower circulating lipids, we performed a secondary 
analysis of a single center, fully randomized, double-blind, 3-phase, 
and placebo-controlled crossover study in patients with varying 
degrees of proteinuric, predialysis CKD, a population at significantly 
increased CVD risk. The full study protocol has been described pre-
viously and was performed with subjects’ written consent and South 
East Scotland research ethics committee approval.20
Patients and Interventions
Twenty-seven patients were enrolled and randomly assigned to receive 
the selective ETA receptor antagonist, sitaxentan 100 mg once-daily, 
matched placebo, or long-acting nifedipine 30 mg once-daily for 6 
weeks in addition to their usual medications. Each phase was separated 
by a minimum 2-week washout period. We included patients aged 18 
to 70 years of age with stable CKD stages 1 to 4 and proteinuria >300 
mg/d. Patients with diabetes mellitus, nephrotic syndrome, significant 
cardiorespiratory comorbidity, peripheral vascular disease, liver di-
sease, and women of childbearing potential were excluded.
Assessments
Patients underwent assessments at baseline, week 3 and week 6 of 
each treatment phase, which included blood sampling for biochem-
ical analyses. Total cholesterol, LDL-C, high-density lipoprotein–as-
sociated cholesterol (HDL-C), triglycerides, lipoprotein(a) [Lp(a)], 
and circulating PCSK9 were also assessed at these timepoints (Figure 
S1 in the online-only Data Supplement).
Sample Collection and Analysis
Blood was collected into serum and EDTA tubes, immediately centri-
fuged at 2500g for 20 minutes at 4°C and stored at −80°C until analysis. 
Lipid parameters were analyzed from stored serum, while PCSK9 was 
analyzed from stored plasma. Total cholesterol, LDL-C, HDL-C, and 
triglycerides were measured by enzymatic colorimetric assays. For total 
cholesterol, the limit of detection and intra-assay and interassay coeffi-
cients of variation (CV) were 0.02 mmol/L, 0.8% and 1.3%, respectively. 
For LDL-C, the limit of detection was 0.03 mmol/L with intra-assay and 
interassay CV of 1.4% and 2.2%, respectively. For HDL-C, the limit of 
detection was 0.06 mmol/L with intra-assay and interassay CV of 1.7% 
and 5.0%, respectively. For triglycerides, the limit of detection was 0.13 
mmol/L with intra-assay and interassay CV of 0.8% and 1.7%, respec-
tively. Lp(a) was quantified using a latex agglutination assay with a limit 
of detection of 0.83 mg/dL and intra-assay and interassay CV of 1.2% and 
3.0%, respectively. PCSK9 was measured using an ELISA (R&D sys-
tems) with a limit of detection of 0.096 ng/mL. Mean recovery of PCSK9 
was 107%, and cross-reactivity was 0% for LDL-R, PCSK1, 3 and 7. The 
intra-assay and interassay CV were 4.1% and 5.6%, respectively.
Table 1. Baseline Study Characteristics
Parameter
Demographic
  Age, y 48±12
  Male (%) 23 (85)
Clinical
  24 h average systolic BP, mm Hg 125±12
  24 h average diastolic BP, mm Hg 78±7
  Pulse wave velocity, m/s 7.9±0.3
Biochemistry
  Creatinine, mg/dL 1.73±0.85
  eGFR, mL/min per 1.73 m2 54±26
  CKD stage by eGFR, n (%)
   1 5 (19)
   2 6 (22)
   3 11 (40)
   4 5 (19)
   5 0
  Urine protein-to-creatinine ratio, mg/mmol 156±29
  Total cholesterol, mg/dL 165±29
  LDL-C, mg/dL 103±32
  HDL-C, mg/dL 43±11
  Triglycerides, mg/dL 143±113
  Lp(a), mg/dL 30±3
  PCSK9, ng/mL 400±117
Medications, n (%)
  Statin 18 (67)
  ACEi 18 (67)
  ARB 11 (41)
  α-blocker 6 (22)
  β-blocker 8 (30)
  Calcium channel blocker 3 (11)
  Diuretic 2 (7)
Values are mean±SE of 3 baseline treatment periods unless stated. 
Conversion factors for units: serum creatinine in mg/dL to μmol/L, ×88.4; urine 
protein-to-creatinine ratio in mg/mmol to mg/g, ÷ 0.113; cholesterol, LDL-C, 
HDL-C in mg/dL to mmol/L, ×0.02586; and triglycerides in mg/dL to mmol/L, 
×0.01129. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, 
angiotensin receptor blocker; BP, blood pressure; CKD, chronic kidney disease; 
eGFR, estimated glomerular filtration rate by modified diet in renal disease 
equation; HDL-C, high-density lipoprotein–associated cholesterol; LDL-C, low-
density lipoprotein–associated cholesterol; Lp(a), lipoprotein(a); and PCSK9, 
proprotein convertase subtilisin/kexin type 9.
Table 2. Baseline Lipid Profiles for Each Study Phase
Parameter Placebo Nifedipine
ET
A
 
Antagonist P Value
Total cholesterol 164±6 167±6 164±6 0.9
LDL-C 99±6 101±6 109±6 0.6
HDL-C 44±2 43±2 40±2 0.6
Triglycerides 116±16 153±20 137±23 0.8
Lp(a) 30±6 31±6 30±6 0.9
PCSK9, ng/mL 400±22 386±24 414±22 0.9
Values are predosing mean±SE, mg/dL unless stated. Analysis by ANOVA. 
Conversion factors for units: cholesterol, LDL-C, and HDL-C in mg/dL to 
mmol/L, ×0.02586 and triglycerides in mg/dL to mmol/L, ×0.01129. HDL-C 
indicates high-density lipoprotein–associated cholesterol; LDL-C, low-density 
lipoprotein–associated cholesterol; Lp(a), lipoprotein(a); and PCSK9, proprotein 
convertase subtilisin/kexin type 9.
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Statistical Analysis
The original study was designed to detect significant changes in pro-
teinuria using data from a prior study,21 where an ETA receptor antag-
onist was administered to 22 subjects in a crossover design leading 
to a reduction in proteinuria of ≈0.7 g/d with an SD of 0.9 g/d. Using 
these data, the current study size had 80% power to detect such a dif-
ference at the 2-sided 5% significance level.
Baseline lipid levels were assessed by repeated measures 1-way 
ANOVA with Tukey correction for multiple comparisons to assess 
carryover and period effect at the start of each treatment phase. A re-
peated measures 3-way ANOVA was used to assess for interactions 
between time, treatment, and statin use for changes in lipids and 
PCSK9. Where Mauchly test indicated the sphericity assumption was 
not met, the Greenhouse-Geisser or Huynh-Feldt correction were used 
as appropriate. Changes from baseline to week 6 within treatment 
phases and between treatments phases at all time points were assessed 
by repeated measures 2-way ANOVA with Sidak and Tukey correc-
tions for multiple comparisons, respectively. Predictors of change in 
PCSK9 concentrations were modeled by linear regression, adjusting 
for potential confounders. Data were analyzed with IBMSPSS (ver-
sion 24) and R (version 3.3.3). Significance was taken at the 5% level.
Results
Baseline patient characteristics are shown in Table 1. Baseline 
mean (±SEM) total cholesterol was 165±29 mg/dL, LDL-C 
103±32 mg/dL, HDL-C 43±11 mg/dL mmol/L, triglycer-
ides 143±113 mg/dL, and Lp(a) 31±3 mg/dL. There were 
Figure 1. Changes in lipid profiles. Bar chart of mean change from baseline of total cholesterol (A), low-density lipoprotein–associated cholesterol (LDL-C); 
B), high-density lipoprotein–associated cholesterol (HDL-C; C), triglycerides (D), and Lp(a) (lipoprotein(a); E) after week 3 and week 6 of dosing with placebo 
(blue bars), nifedipine (green bars), and selective ETA receptor antagonism (red bars). ***P<0.001 for change at week 6 vs baseline; 
∙∙∙P<0.001 for change at 
timepoint vs placebo and nifedipine; and ∙P<0.05 for change at timepoint vs placebo or nifedipine. Analysis by ANOVA. Error bars are SE of mean. Conversion 
factors for units: cholesterol, LDL-C, and HDL-C in mg/dL to mmol/L, ×0.02586; and triglycerides in mg/dL to mmol/L, ×0.01129.
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no differences in circulating lipids at the start of each study 
phase (Table 2). Eighteen (67%) patients were prescribed a 
statin, while 24 (89%) patients were prescribed either an ACEi 
(angiotensin-converting enzyme inhibitor) or ARB (angio-
tensin receptor blocker).
As previously reported,20 6 weeks dosing with a selective 
ETA antagonist and nifedipine reduced BP and arterial stiff-
ness similarly, but ETA antagonism reduced proteinuria to a 
greater extent than nifedipine. Placebo did not affect these 
parameters. All patients completed all 3 phases, and no serious 
adverse events were recorded during any treatment phase.20
In terms of effects on circulating lipids and PCSK9, there 
were no significant 3-way interactions between time, treat-
ment, and statin use but significant interactions between time 
and treatment were present and analyzed further (Table S1). 
Total cholesterol, LDL-C, and HDL-C were unaffected by 
placebo or nifedipine. In contrast, 6 weeks of ETA antagonism 
led to a fall in total cholesterol of 18±2 mg/dL, a reduction of 
≈11% (P<0.001 versus baseline; P<0.001 versus nifedipine 
and placebo at week 6, Figure 1A). The reduction in total cho-
lesterol seen with ETA antagonism comprised a fall in LDL-C 
of 21±3 mg/dL (≈20% reduction, P<0.001 versus baseline; 
P<0.001 versus nifedipine and placebo at week 6, Figure 1B) 
and an increase in HDL-C of 5±1 mg/dL (≈14% increase, 
P<0.001 versus baseline; P<0.001 versus nifedipine and pla-
cebo at week 6, Figure 1C). ETA antagonism also led to reduc-
tions in triglycerides of 39±10 mg/dL (≈20% fall, P<0.001 
versus baseline; P<0.05 versus nifedipine and placebo at week 
6, Figure 1D) and in Lp(a) of 3.2±0.8 mg/dL (≈15% fall, 
P<0.05 versus baseline and placebo at week 6, Figure 1E). 
Detailed effects of ETA antagonism compared with nifedipine 
and placebo are shown in Tables S2 through S7 with indi-
vidual patient responses shown in Figures S2 through S6.
Mean (±SEM) baseline plasma PCSK9 concentration 
was 400±117 ng/mL and did not differ between the three 
phases of the study (Table 2). After 6 weeks of ETA receptor 
antagonism, PCSK9 fell by −81±13 ng/mL (≈20% reduc-
tion, P <0.001 versus baseline; P<0.05 versus nifedipine and 
placebo, Figure 2 and Figure S7). Reductions in circulating 
PCSK9 during ETA antagonism were observed to occur with 
simultaneous reductions in total cholesterol, LDL-C, and to a 
lesser degree with triglycerides, while also associating with 
increases in HDL-C (Figure 3). No relationship could be dem-
onstrated for the nifedipine and placebo phases.
Linear regression modeling indicated that treatment with 
ETA antagonism was an independent predictor of change in 
PCSK9 concentration at 6 weeks after adjustment for age, sex, 
statin treatment, and baseline CVD risk factors (adjusted β, 73 
ng/mL; 95% CI, −131 to −16; P=0.01, Table S8). In addition, 
selective ETA antagonism remained an independent predictor of 
change in PCSK9 concentration at 6 weeks after adjustment for 
change in proteinuria, BP, and pulse wave velocity (Table S9).
Discussion
Our study has several important findings. We provide new 
evidence of the broad beneficial effects of selective ETA re-
ceptor antagonism on circulating lipids in patients with vary-
ing degrees of predialysis CKD and residual proteinuria. 
Here, medium-term dosing with an ETA antagonist resulted 
in clinically-relevant reductions in total cholesterol, LDL-C, 
and triglycerides with a significant increase in HDL-C. In 
addition, we saw a significant fall in Lp(a). Importantly, these 
improvements occurred in patients at high CVD risk, the ma-
jority of whom were already receiving recommended CVD 
prevention therapy with a statin and either an ACEi or ARB. 
Furthermore, we have shown that these lipid-lowering effects 
occurred with a concurrent reduction in circulating PCSK9. 
This previously unreported finding supports a link between 
the endothelin system and cholesterol homeostasis.
Lowering LDL-C has been shown to reduce the risk of 
major atherosclerotic events in a wide range of patients with 
CKD.4 However, despite current lipid-lowering treatments, 
a number of patients fail to achieve target LDL-C.6 This is 
mirrored in our cohort of patients whose mean baseline fast-
ing LDL-C was above the recommended 100 mg/dL despite 
a high rate of statin use.6,22 Additionally, of the 18 patients 
(67%) receiving a statin, 11 were also prescribed the cho-
lesterol-absorption inhibitor, ezetimibe. Thus, from a clinical 
perspective, it is important that the effects observed with ETA 
receptor antagonism occurred on top of currently available 
therapies. Furthermore, suboptimal dosing and discontin-
uation of statins because of adverse effects remain signifi-
cant challenges in clinical practice.7 For example, the risk 
of statin-induced myopathy is increased in patients with im-
paired renal function.23 Therefore, alternative agents, which 
might improve lipid profiles in this particularly high-risk 
group, while conferring broader CVD risk protection, would 
be of major clinical value.
Previous reports of the lipid-lowering effects of ET re-
ceptor antagonism are limited. Kowala et al14 demonstrated 
that selective ETA antagonism lowered total cholesterol, LDL-
C, and triglycerides in hyperlipidemic hamsters, and this 
reduced aortic arch atherosclerosis. Data from clinical stud-
ies are conflicting with some noting an improvement in lipid 
profiles15,17 whereas others have shown no effect.18,24 Studies 
in CKD are limited to those with diabetic nephropathy. In a 
study using the mixed ETA/B antagonist, avosentan, the authors 
Figure 2. Change in circulating PCSK9 (proprotein convertase subtilisin/
kexin type 9). Bar chart of mean change in plasma PCSK9 from baseline 
after week 3 and week 6 of dosing with placebo (blue bars), nifedipine 
(green bars), and selective ETA (endothelin-A) receptor antagonist (red 
bars). ***P<0.001 for selective ETA receptor antagonist at week 6 vs 
baseline; analysis by paired t tests. ∙P<0.05 for change at timepoint vs 
placebo and nifedipine. Analysis by ANOVA. Error bars are SE of mean.
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reported a ≈7% reduction in total cholesterol after 12 weeks 
dosing but found no effect on triglycerides; they did not report 
on LDL-C or HDL-C.16 Using the selective ETA antagonist, 
atrasentan, de Zeeuw et al19 showed similar effects after 12 
weeks on total cholesterol, LDL-C, and triglycerides to those 
seen in the current study but no change in HDL-C. Our data 
add to these studies and also demonstrate a beneficial effect 
on HDL-C and Lp(a), as well as suggesting a potential mech-
anism through a reduction of circulating PCSK9. Interestingly, 
these effects on lipids may relate to the relative ETA:ETB re-
ceptor selectivity of the drug used: bosentan (nonselective) no 
effect on cholesterol18; avosentan (ETA:ETB, ≈300:1) ≈7% re-
duction in cholesterol16; atrasentan (ETA:ETB, ≈1200:1) ≈9% 
reduction in cholesterol19; and sitaxentan (ETA:ETB, ≈6500:1) 
≈11% reduction in cholesterol.25
Beyond its role in cholesterol homeostasis, a link between 
circulating PCSK9 concentration and CVD risk has emerged. 
Leander et al26 recently showed in a middle-aged, non-CKD 
population that a greater circulating PCSK9 was associated 
with a higher risk of incident CVD, particularly thrombotic 
events. This remained the case even after adjusting for tradi-
tional CVD risk factors including LDL-C and statin use. The 
mean PCSK9 level in our study (≈400 ng/mL) is comparable 
to the highest risk quartile identified by Leander et al26 and 
is similar to that seen in other studies in CKD.27 The greater 
CVD risk associated with elevated PCSK9 concentrations 
may be due in part to its positive association with elevated 
Lp(a), a modified LDL species that can impair endogenous fi-
brinolysis.28 A recent meta-analysis of >29 000 patients found 
an independent and near-linear association between both 
Figure 3. Change in lipids and circulating PCSK9 (proprotein convertase subtilisin/kexin type 9). Scatter plots of individual percentage changes from 
baseline in total cholesterol (A), low-density lipoprotein–associated cholesterol (LDL-C); B), high-density lipoprotein–associated cholesterol (HDL-C); C), 
and triglycerides (D) after 6 weeks of treatment vs individual percentage change in plasma PCSK9. Blue dots denote subjects receiving placebo; green dots 
denote subjects receiving nifedipine; and red dots denote subjects receiving selective ETA (endothelin-A) receptor antagonist.
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elevated baseline and on-statin Lp(a) concentrations and CVD 
risk.29 This association holds true in CKD as shown in ≈3500 
patients with CKD from the Chronic Renal Insufficiency 
Cohort where a higher concentration of Lp(a) was independ-
ently associated with a greater risk of incident myocardial 
infarction and death during ≈7.5 years follow-up.30 Targeting 
these 2 novel markers of CVD risk using conventional treat-
ments is challenging as statins increase circulating PCSK931 
and are ineffective at lowering Lp(a).32 Our data suggest that 
ETA receptor antagonism reduces both.
Inhibition of circulating PCSK9 using novel humanized 
monoclonal antibodies results in marked reductions in LDL-
C, and uniquely Lp(a), in clinical trials of patients both on 
and off statins.9,10 These agents bind to circulating PCSK9, 
lowering plasma levels by ≈90%.33 However, their widespread 
use is limited by cost; the current list price of evolocumab 
is more than $14 000 a year per patient.34 In our study, ETA 
receptor antagonism reduced circulating PCSK9 by ≈20%, 
which was associated with significant improvements in lipids. 
The pattern of improvement in lipid profiles with ETA receptor 
antagonism, particularly the significant reductions in Lp(a) 
(≈16%), is strikingly similar to that observed in clinical trials 
of PCSK9 inhibitors9,10 (Figure S8) suggesting that these are 
secondary to a reduction in circulating PCSK9.
Our observed reduction in PCSK9 during ETA antagonism 
occurred independently of the major recognized vascular and 
renal effects of this drug class, namely reductions in BP, arte-
rial stiffness, and proteinuria. This suggests novel and specific 
links between the endothelin system and PCSK9, as proposed 
in Figure 4. Systemic inflammation, podocyte injury, and 
proteinuria are features of CKD and in which ETA receptor 
activation plays a key role.13 All 3 have also been shown to 
increase tissue and circulating PCSK9 expression in mice.11,12 
However, there was inconsistent evidence in these studies of 
a concurrent upregulation of SREBP2 (sterol regulatory ele-
ment binding protein 2) and HNF1α (hepatic nuclear factor 
1α), the principle promoters of PCSK9 expression. Induction 
of endoplasmic reticulum stress in murine renal proximal tu-
bular cells has been shown to increase SREBP2 expression 
with subsequent lipid accumulation and apoptosis.35 In a sep-
arate study, using the same model, selective ETA antagonism 
reduced endoplasmic reticulum stress and apoptosis of prox-
imal tubular cells.36 These studies did not examine PCSK9 ex-
pression, but recent work suggests that increased renal PCSK9 
Figure 4. Proposed pathways linking the endothelin system, PCSK9 (proprotein convertase subtilisin/kexin type 9) expression and cholesterol in chronic 
kidney disease. The liver is the major site of PCSK9 expression with HNF1α (hepatic nuclear factor 1α) and SREBP2 (sterol regulatory element binding 
protein 2) its principle promoters.4 Animals studies have shown that insulin binding to hepatocytes prevents nuclear translocation of HNF1α thus reducing 
PCSK9 transcription.5 ET-1 (endothelin-1) impairs hepatocyte insulin sensitivity6 which can be ameliorated by selective ETA receptor antagonism
7,8 and so 
may restore the inhibitory effect of insulin on HNF1α-mediated PCSK9 transcription in hepatocytes. Whether ET-1 has direct effects on HNF1α or SREBP2 
in hepatocytes is unknown. Systemic inflammation can increase both hepatic and renal PCSK9 expression with a concurrent reduction in LDL-R (low 
density lipoprotein receptor) expression9 and a rise in low-density lipoprotein–associated cholesterol (LDL-C). In the vasculature, ET-1 has proinflammatory 
effects mediated predominantly through ETA receptor activation.
10 In the kidney, podocyte damage is associated with increased circulating and renal PCSK9 
expression, notably localized to proximal tubular cells in murine models.11 The relevance of renal PCSK9 expression to the circulating PCSK9 pool and lipids 
needs further clarification. Interestingly, ER (endoplasmic reticulum) stress leads to an upregulation of SREBP2 in renal proximal tubular cells with subsequent 
apoptosis,12 but effects on PCSK9 expression here are unexplored. However, selective ETA antagonism has been shown to ameliorate podocyte injury
13 and 
proximal tubule ER stress14 suggesting a potential role in renal PCSK9 expression.
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expression after podocyte injury/ablation is also localized to 
proximal tubular cells.12
Other preclinical data suggest an important role for insulin 
in reducing hepatic PCSK9 expression by preventing nuclear 
translocation of HNF1α.37 ET-1 has been to shown to promote 
hepatic insulin resistance38 which can be restored by ETA re-
ceptor antagonism in Zucker fatty rats39 and in man40 with a 
subsequent improvement in glucose metabolism. Finally, in-
flammation may act as an important shared pathway as vascular 
smooth muscle cells, the predominant site of ETA receptor ex-
pression, have recently been shown to express PCSK941 which 
can be upregulated by inflammatory stimuli in vitro.42
The collected published data link the endothelin system, 
PCSK9 and lipid homeostasis (Figure 4) and provide a plausible 
mechanistic basis for our clinical observations that should be 
explored further in future studies. We recognize the small size of 
our study as well as its medium-term duration and observational 
nature and while our data are secondary analyses, they originate 
from a well-designed, fully randomized, placebo-controlled clin-
ical trial with no measurable evidence of carryover or period 
effects. We acknowledge that while the 2-week washout period 
between phases was designed to ensure adequate drug elimina-
tion, persisting effects on cholesterol metabolism cannot be fully 
excluded, although our detailed analyses show no sign of this. We 
demonstrate clear, consistent benefits on circulating lipids with 
ETA antagonism and provide novel insight into links between the 
endothelin system and cholesterol homeostasis in kidney disease.
Perspectives
Medium-term selective ETA antagonism improves lipid pro-
files in optimally-managed patients with CKD. Our data sug-
gest that the lipid-lowering effects of ETA antagonism may be 
achieved through a reduction in circulating PCSK9. Alongside 
recognized reductions in BP, proteinuria and arterial stiffness, 
ETA receptor antagonism offers a novel strategy to reduce 
CVD risk in patients with CKD. Current larger clinical trials 
of selective ETA antagonism alone43 or in combination with 
angiotensin II receptor blockade43,44 in patients with protein-
uric CKD should help confirm the current observations.
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What Is New?
•	 In patients with chronic kidney disease, treatment with a selective ETA 
(endothelin-A) antagonist led to clinically-relevant reductions in circu-
lating lipids.
•	 Interestingly, these lipid-lowering effects occurred alongside a reduction 
in circulating PCSK9 (proprotein convertase subtilisin/kexin type 9).
What Is Relevant?
•	Patients with chronic kidney disease are at high cardiovascular risk. 
Dyslipidemia is common and despite the use of statins, many of these 
patients continue to have elevated lipids.
•	The beneficial effects seen here were in patients at high cardiovascular 
risk, the majority of whom were already receiving recommended cardio-
vascular disease prevention therapy.
Summary
In patients with predialysis chronic kidney disease, selective ET
A
 
receptor antagonism reduces circulating lipids. These effects are 
seen on top of statin therapy and may be mediated through a re-
duction in PCSK9. These previously unreported findings support a 
link between the endothelin system and cholesterol homeostasis.
Novelty and Significance
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